Story
Natera Stock Hits All-Time High, Surging 27% on Japan Approval and Positive Study Data
Summary
Shares of diagnostics firm Natera Inc. surged to an all-time high in September, driven by a key regulatory approval in Japan, promising clinical study results, and upbeat financial guidance from management.
Shares of diagnostics company Natera Inc. (NASDAQ:NTRA) rallied approximately 27% in September, hitting a new all-time high amid a series of positive catalysts. The stock closed at $408.79 on September 24, according to Investing.com, pushing its market capitalization to roughly $58.9 billion.
Key Catalysts Drive Rally
The stock's sharp ascent was fueled by three distinct developments announced in the past week. These events provided investors with new confidence in the company's flagship liquid biopsy test, Signatera, and its long-term financial outlook.
Key developments included:
- Regulatory Approval in Japan: On September 22, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved Signatera as a companion diagnostic for muscle-invasive bladder cancer. Natera is targeting a commercial launch in the first half of 2027.
- Promising Cancer Study: On September 18, the company presented results from a large study on minimal residual disease in lung cancer. The data from 1,129 patients showed that individuals who tested negative with Signatera had a 25-percentage-point higher rate of recurrence-free survival at three years.
- Upgraded Financial Guidance: At a Morgan Stanley healthcare conference on September 22, Natera's management outlined a strategic path toward achieving gross margins above 70% as adoption of its testing franchises grows.
AdWall Street Response
The news prompted several Wall Street analysts to raise their price targets for Natera. UBS increased its target to $435 from $290, Guggenheim moved its target to $360, and TD Cowen lifted its target to $340, with all three maintaining Buy ratings, as reported by Investing.com.
The stock's recent performance has outpaced the average analyst expectation. According to the source, the consensus price target from 23 analysts stood at $330.83, a level Natera's shares have already surpassed. The stock's performance contrasts with the broader S&P 500 Health Care index, which was down slightly for the month.
Read next
More on Stocks
Firms Linked to Sanctioned Chinese Textile Giant Esquel Shipping Apparel to US, Records Show
An investigation reveals three Vietnamese garment makers with deep corporate and supply chain ties to sanctioned Chinese firm Esquel Group have exported millions in cotton goods to U.S. brands, raising questions about sanctions enforcement.
SMBC in Advanced Talks to Raise VPBank Stake to 20%, Sources Say
Japan's Sumitomo Mitsui Banking Corp is negotiating to increase its holding in Vietnam's VPBank from 15% to approximately 20%, according to people familiar with the matter, though the two sides reportedly remain at odds over valuation.
Bitget Halts Withdrawals After $351.6 Million Hot Wallet Breach
Cryptocurrency exchange Bitget has temporarily suspended withdrawals after identifying unauthorized transfers totaling approximately $351.6 million from its hot wallets. The company stated the losses are fully covered by its User Protection Fund.
Japanese Bank Stocks Rally as Bond Yields Hit 30-Year High
Major Japanese banking shares surged on Friday, driven by a spike in government bond yields to a three-decade peak and mounting expectations of further interest rate hikes from the Bank of Japan.